Literature DB >> 20806363

Non-metastatic osteosarcoma of the extremities in children aged 5 years or younger.

Massimo Eraldo Abate1, Alessandra Longhi, Stefano Galletti, Stefano Ferrari, Gaetano Bacci.   

Abstract

BACKGROUND: The occurrence of high-grade osteosarcoma is rare in children aged 5 years or younger and only limited series or case reports have been described.
METHODS: The records of patients aged 5 years or younger with non-metastatic high-grade osteosarcoma of the extremities treated with surgery and adjuvant or neo-adjuvant chemotherapy at Rizzoli Institute between 1972 and 1999 were retrospectively evaluated in relation to gender, primary tumor site, histological subtype, surgical treatment, chemotherapy-induced tumor necrosis, 5- and 10-year event-free survival (EFS), and rate of local recurrence. Data were compared to patients aged 6-40 years entered with the same diagnosis and over the same time interval.
RESULTS: Data from 20 patients were collected. Comparing these data with those from 1,106 patients 6-40 years of age only two main differences resulted: the younger group showed a higher rate for fibroblastic subtype (P < 0.01) and for amputation surgery (P < 0.01). Among the two groups, no statistical difference was observed for the 5-year EFS (60% vs. 53.8%; P = 0.6) and 10-year EFS (60% vs. 52.1%; P = 0.5). The rate of local recurrence was 5.0% and 5.4%.
CONCLUSIONS: These findings suggest that in non-metastatic osteosarcoma of the extremities outcome and clinical characteristics are similar among children 5 years of age or younger and older patients. However, in the younger group we have observed a significant higher rate of fibroblastic subtype as well as a significant higher rate of mutilating surgery. Pediatr Blood Cancer. Copyright 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20806363     DOI: 10.1002/pbc.22567

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  8 in total

1.  Bisphosphonate-Functionalized Hydroxyapatite Nanoparticles for the Delivery of the Bromodomain Inhibitor JQ1 in the Treatment of Osteosarcoma.

Authors:  Victoria M Wu; Jarrett Mickens; Vuk Uskoković
Journal:  ACS Appl Mater Interfaces       Date:  2017-07-28       Impact factor: 9.229

2.  Magnetic calcium phosphates nanocomposites for the intracellular hyperthermia of cancers of bone and brain.

Authors:  Alessio Adamiano; Victoria M Wu; Francesca Carella; Gianrico Lamura; Fabio Canepa; Anna Tampieri; Michele Iafisco; Vuk Uskoković
Journal:  Nanomedicine (Lond)       Date:  2019-05       Impact factor: 5.307

3.  Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.

Authors:  Grace-Ifeyinwa Onimoe; Aiguo Liu; Li Lin; Chang-Ching Wei; Eric B Schwartz; Deepak Bhasin; Chenglong Li; James R Fuchs; Pui-kai Li; Peter Houghton; Amanda Termuhlen; Thomas Gross; Jiayuh Lin
Journal:  Invest New Drugs       Date:  2011-02-22       Impact factor: 3.850

Review 4.  Update on Osteosarcoma.

Authors:  Rebekah Belayneh; Mitchell S Fourman; Sumail Bhogal; Kurt R Weiss
Journal:  Curr Oncol Rep       Date:  2021-04-21       Impact factor: 5.075

5.  Clinical characteristics and prognosis of osteosarcoma in young children: a retrospective series of 15 cases.

Authors:  Maud A M Guillon; Pierre M J Mary; Laurence Brugière; Perrine Marec-Bérard; Hélène D Pacquement; Claudine Schmitt; Jean-Marc Guinebretière; Marie-Dominique P Tabone
Journal:  BMC Cancer       Date:  2011-09-24       Impact factor: 4.430

6.  Osteosarcoma: a comprehensive review.

Authors:  Amirhossein Misaghi; Amanda Goldin; Moayd Awad; Anna A Kulidjian
Journal:  SICOT J       Date:  2018-04-09

7.  Ewing sarcoma of the bone in children under 6 years of age.

Authors:  Maria Antonietta De Ioris; Arcangelo Prete; Raffaele Cozza; Marta Podda; Carla Manzitti; Andrea Pession; Elisabetta Schiavello; Benedetta Contoli; Rita Balter; Franca Fagioli; Gianni Bisogno; Loredana Amoroso; Franco Locatelli; Roberto Luksch
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

8.  Interleukin-22 Promotes Osteosarcoma Cell Proliferation and Invasion via STAT3 Activation.

Authors:  Panpan Li; Xin Shi; Yonghui Xu; Binggang Zhong; Yu Lu; Yong Sun
Journal:  Med Sci Monit       Date:  2018-11-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.